Search research articles
Contact Us
Filters
Showing results (1-10 of 154) with videos related to
Page
of 16
Sort By:
Oncology (Williston Park, N.Y.)
|
September 17, 2014
Management of the patient with postpartum breast cancer
Virginia F Borges
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 28, 2021
Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?
Virginia F Borges
Journal of the National Cancer Institute
|
December 1, 2021
The Expanded Role of Ovarian Suppression for Young Women's Breast Cancer: An Era of Patient-Tailored Decision Making
Virginia F Borges
Expert Opinion on Pharmacotherapy
|
February 16, 2010
Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer
Peter Kabos, Virginia F Borges
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2011
The era of high-dose chemotherapy for breast cancer: revisiting a troubled quest
Virginia F Borges, Anthony D Elias
Cancer
|
November 17, 2011
Pregnancy-associated breast cancer: an entity needing refinement of the definition
Virginia F Borges, Pepper J Schedin
Clinical Breast Cancer
|
May 4, 2005
Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women
Steven E Come, Virginia F Borges
The New England Journal of Medicine
|
August 26, 2022
What <i>Dobbs</i> Means for Patients with Breast Cancer
Nicole T Christian, Virginia F Borges
Cancer Prevention Research (Philadelphia, Pa.)
|
July 10, 2021
Vitamin D as a Potential Preventive Agent For Young Women's Breast Cancer
Sarah M Bernhardt, Virginia F Borges, Pepper Schedin
Current Opinion in Gastroenterology
|
October 13, 2006
Update on cancer vaccines
Virginia F Borges, Donald Kufe, David E Avigan
Page
of 16
Search research articles
Search
Showing results (1-10 of 154) with videos related to
Sort By:
Page
of 16
Oncology (Williston Park, N.Y.)
|
September 17, 2014
Management of the patient with postpartum breast cancer
Virginia F Borges
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 28, 2021
Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?
Virginia F Borges
Journal of the National Cancer Institute
|
December 1, 2021
The Expanded Role of Ovarian Suppression for Young Women's Breast Cancer: An Era of Patient-Tailored Decision Making
Virginia F Borges
Expert Opinion on Pharmacotherapy
|
February 16, 2010
Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer
Peter Kabos, Virginia F Borges
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2011
The era of high-dose chemotherapy for breast cancer: revisiting a troubled quest
Virginia F Borges, Anthony D Elias
Cancer
|
November 17, 2011
Pregnancy-associated breast cancer: an entity needing refinement of the definition
Virginia F Borges, Pepper J Schedin
Clinical Breast Cancer
|
May 4, 2005
Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women
Steven E Come, Virginia F Borges
The New England Journal of Medicine
|
August 26, 2022
What <i>Dobbs</i> Means for Patients with Breast Cancer
Nicole T Christian, Virginia F Borges
Cancer Prevention Research (Philadelphia, Pa.)
|
July 10, 2021
Vitamin D as a Potential Preventive Agent For Young Women's Breast Cancer
Sarah M Bernhardt, Virginia F Borges, Pepper Schedin
Current Opinion in Gastroenterology
|
October 13, 2006
Update on cancer vaccines
Virginia F Borges, Donald Kufe, David E Avigan
Page
of 16